Regeneron Pharmaceuticals Inc (REGN)

Fixed asset turnover

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Revenue (ttm) US$ in thousands 13,044,200 13,025,200 12,601,200 12,306,100 12,113,500 13,654,100 14,171,800 16,451,800 16,014,400 13,499,700 12,328,800 9,147,000 8,455,000 8,201,600 7,974,500 7,957,900 7,839,900 7,598,200 7,213,600 6,889,000
Property, plant and equipment US$ in thousands 3,540,700 4,006,100 3,922,600 3,880,900 3,142,700 3,704,200 3,637,700 3,556,400 3,482,200 3,395,700 3,358,500 3,262,600 3,221,600 3,138,300 3,031,400 2,944,600 2,890,400 2,771,400 2,676,600 2,612,800
Fixed asset turnover 3.68 3.25 3.21 3.17 3.85 3.69 3.90 4.63 4.60 3.98 3.67 2.80 2.62 2.61 2.63 2.70 2.71 2.74 2.70 2.64

December 31, 2023 calculation

Fixed asset turnover = Revenue (ttm) ÷ Property, plant and equipment
= $13,044,200K ÷ $3,540,700K
= 3.68

Regeneron Pharmaceuticals, Inc.'s fixed asset turnover has exhibited some fluctuations over the past eight quarters. The ratio peaked at 4.64 in Q1 2022 and has since shown a general declining trend, reaching a low of 3.16 in Q4 2023.

A fixed asset turnover ratio measures a company's ability to generate revenue from its fixed assets. A higher ratio indicates that the company is more efficient in utilizing its fixed assets to generate sales.

The recent decrease in Regeneron's fixed asset turnover may indicate a decrease in the company's efficiency in utilizing its fixed assets to generate revenue. It is essential for the company to analyze the reasons behind this trend and take necessary steps to improve asset utilization efficiency in the future.

Overall, while there have been fluctuations in Regeneron Pharmaceuticals, Inc.'s fixed asset turnover ratio, the company should focus on optimizing the usage of its fixed assets to enhance operational efficiency and profitability.


Peer comparison

Dec 31, 2023


See also:

Regeneron Pharmaceuticals Inc Net Fixed Asset Turnover (Quarterly Data)